1. NO reverse split 2. Partnership with milestone payments totaling $250M+ 3. Priority FDA Review Granted 4. Stock at 3+ 1 out of 4 ain't BAD. 3 will happen after 2 & 1. 1 will occur after 2 before 3. Whereas 4 will happen after 1, 2 & 3. For further in depth analysis ask DEW :-) <!--Beg_Sig-->